BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10471096)

  • 21. Effect of atypical antipsychotic drugs on 5-HT2 receptors in the rat orbito-frontal cortex: an in vivo electrophysiological study.
    Bergqvist PB; Dong J; Blier P
    Psychopharmacology (Berl); 1999 Mar; 143(1):89-96. PubMed ID: 10227084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo electrophysiological characterization of 5-HT receptors in the guinea pig head of caudate nucleus and orbitofrontal cortex.
    el Mansari M; Blier P
    Neuropharmacology; 1997; 36(4-5):577-88. PubMed ID: 9225283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist.
    Nichols DE; Frescas S; Marona-Lewicka D; Huang X; Roth BL; Gudelsky GA; Nash JF
    J Med Chem; 1994 Dec; 37(25):4346-51. PubMed ID: 7996545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-Hydroxytryptamine-stimulated inositol phospholipid hydrolysis in rat cerebral cortex slices: pharmacological characterization and effects of antidepressants.
    Kendall DA; Nahorski SR
    J Pharmacol Exp Ther; 1985 May; 233(2):473-9. PubMed ID: 2987487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats.
    Willins DL; Meltzer HY
    J Pharmacol Exp Ther; 1997 Aug; 282(2):699-706. PubMed ID: 9262333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors.
    Zhang W; Bymaster FP
    Psychopharmacology (Berl); 1999 Jan; 141(3):267-78. PubMed ID: 10027508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs.
    Newton RA; Phipps SL; Flanigan TP; Newberry NR; Carey JE; Kumar C; McDonald B; Chen C; Elliott JM
    J Neurochem; 1996 Dec; 67(6):2521-31. PubMed ID: 8931486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The serotonin 5-HT2C receptor is a prominent serotonin receptor in basal ganglia: evidence from functional studies on serotonin-mediated phosphoinositide hydrolysis.
    Wolf WA; Schutz LJ
    J Neurochem; 1997 Oct; 69(4):1449-58. PubMed ID: 9326273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-Hydroxytryptamine-induced phosphoinositide hydrolysis and Ca2+ mobilisation in canine cultured aorta smooth muscle cells.
    Chiu CT; Tsao HL; Fan LW; Wang CC; Chien CS; Yang CM
    Cell Signal; 1999 May; 11(5):361-70. PubMed ID: 10376810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex.
    Pehek EA; Nocjar C; Roth BL; Byrd TA; Mabrouk OS
    Neuropsychopharmacology; 2006 Feb; 31(2):265-77. PubMed ID: 15999145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release.
    Ichikawa J; Dai J; Meltzer HY
    Brain Res; 2001 Jul; 907(1-2):151-5. PubMed ID: 11430898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the 5-HT2A receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) on plasma glucose and glucagon levels of rats.
    Sugimoto Y; Yamada J
    Biol Pharm Bull; 2000 Dec; 23(12):1521-3. PubMed ID: 11145190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific labelling of serotonin 5-HT(1B) receptors in rat frontal cortex with the novel, phenylpiperazine derivative, [3H]GR125,743. A pharmacological characterization.
    Millan MJ; Newman-Tancredi A; Lochon S; Touzard M; Aubry S; Audinot V
    Pharmacol Biochem Behav; 2002 Apr; 71(4):589-98. PubMed ID: 11888550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inactivation of 5-HT1A and [3H]5-HT binding sites by N-ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinoline (EEDQ) in rat brain.
    Subhash MN; Srinivas BN; Vinod KY; Jagadeesh S
    Neurochem Res; 1998 Oct; 23(10):1321-6. PubMed ID: 9804289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-hydroxytryptamine(2A) receptors regulate sympathetic nerves constricting the cutaneous vascular bed in rabbits and rats.
    Blessing WW; Seaman B
    Neuroscience; 2003; 117(4):939-48. PubMed ID: 12654345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional subsensitivity of 5-HT2A and 5-HT2C receptors mediating hyperthermia following acute and chronic treatment with 5-HT2A/2C receptor antagonists.
    Mazzola-Pomietto P; Aulakh CS; Tolliver T; Murphy DL
    Psychopharmacology (Berl); 1997 Mar; 130(2):144-51. PubMed ID: 9106912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex.
    Ichikawa J; Dai J; Meltzer HY
    Brain Res; 2002 Jun; 939(1-2):34-42. PubMed ID: 12020849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols.
    Cussac D; Newman-Tancredi A; Quentric Y; Carpentier N; Poissonnet G; Parmentier JG; Goldstein S; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Mar; 365(3):242-52. PubMed ID: 11882920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of apparent receptor reserve at postsynaptic 5-hydroxytryptamine1A receptors negatively coupled to adenylyl cyclase activity in rat hippocampal membranes.
    Yocca FD; Iben L; Meller E
    Mol Pharmacol; 1992 Jun; 41(6):1066-72. PubMed ID: 1352034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined treatment with citalopram and buspirone: effects on serotonin 5-HT2A and 5-HT2C receptors in the rat brain.
    Syvälahti E; Penttilä J; Majasuo H; Pälvimäki EP; Laakso A; Hietala J
    Pharmacopsychiatry; 2006 Jan; 39(1):1-8. PubMed ID: 16453246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.